KOSPIBiotech & Pharma004720

PharmGen Science

₩2,930▲ 0.69%2026-11-18 close
Market Cap
₩66.4B
Turnover
₩6,461,770
Volume
2.2K
Shares out.
22.7M
PER
—
PBR
0.5×
EPS
-₩7,069
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Cost Pressure After a Loss as the Drug Pipeline Expands

PharmGen Science swung to a net loss in 2025 after an affiliate impairment. Its core sales kept rising, but SG&A and R&D costs are weighing on profitability.

  1. 1

    Revenue rose for three consecutive years from 2023 through 2025, but growth slowed to 1.0% in 2025.

  2. 2

    The operating margin fell from 6.2% in 2024 to 3.5% in 2025, mainly because the SG&A ratio rose.

  3. 3

    The 2025 net loss attributable to controlling shareholders of KRW 116.7 billion reflects equity-method valuation and impairment on an affiliate stake.

  4. 4

    The Company has posted net losses attributable to controlling shareholders for five consecutive quarters from Q3 2025 to Q3 2026, totaling KRW 134.4 billion over the latest four quarters.

  5. 5

    The Company returned to operating profit in Q1 2026, but Q3 2026 operating profit of KRW 932 million fell 32.2% year on year.

02

Business structure

PharmGen Science is a mid-sized pharmaceutical company whose predecessor was Sudo Pharmaceutical Industrial, founded in August 1966. Its portfolio centers on prescription drugs for the circulatory and digestive systems, and prescription drugs account for more than 90% of sales.

The business is split into pharmaceuticals, healthcare and other segments. In 2023 the pharmaceutical segment made up 94.6% of revenue, healthcare 5.3% and other 0.1%. On a standalone basis for Q1 2026, pharmaceutical sales were KRW 37.83 billion, down year on year, and healthcare sales shrank to KRW 1.23 billion.

Other-segment sales rose to KRW 4.27 billion and offset most of the decline in the two core segments. Some reporting says it is hard to conclude that the rise in other-segment sales reflects rental income alone.

Key products are the antihypertensive Bardipin tablet, the lipid-lowering Libatin tablet and the reflux esophagitis and ulcer drug Esmax tablet. Bardipin sales were KRW 2.01 billion in Q1 2025. The healthcare business centers on health functional foods and cosmetics.

The pipeline includes five drug candidates: a liver-specific MRI contrast agent, RD1301 for inflammatory bowel disease, RD1304 and RD1305 for reflux esophagitis, and RD5306, a long-acting obesity candidate.

The Company aims to out-license these to large domestic and overseas pharmaceutical companies, even before Phase 1.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩41.5B₩1.4B3.3%
2025Q4₩42.8B-₩800M−1.8%
2026Q1₩43.3B₩1.8B4.1%
2026Q2₩47.7B₩1.8B3.8%
2026Q3₩44.6B₩900M2.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩150.9B₩7.5B₩70.1B5.0%33.8%53.2%
2023₩166.8B₩9.1B₩5.7B5.5%2.5%47.2%
2024₩171.3B₩10.6B₩2.8B6.2%1.1%45.7%
2025₩173.1B₩6B-₩116.7B3.5%−79.7%33.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 150.9 billion in 2022 to KRW 166.8 billion in 2023 (up 10.5% year on year), KRW 171.3 billion in 2024 (up 2.7%) and KRW 173.1 billion in 2025 (up 1.0%). Revenue increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Growth, however, slowed sharply from 10.5% in 2023 to 1.0% in 2025. Operating profit rose from KRW 7.47 billion in 2022 to KRW 9.13 billion in 2023 (up 22.1%) and KRW 10.6 billion in 2024 (up 16.6%), crossing KRW 10 billion for the first time since the Company was founded.

It then fell 43.8% to KRW 5.99 billion in 2025. The operating margin moved from 5.0% in 2022 and 5.5% in 2023 to 6.2% in 2024, then dropped to 3.5% in 2025. The cost of sales ratio improved to 35.5% in 2025, but the SG&A ratio rose to 61.1% from 56.9%, which pressured profitability.

Q1 2026 R&D spending was KRW 3.4 billion, more than double the KRW 1.4 billion of Q1 2025, and the Company cited R&D and CSO fees as the main drivers of higher SG&A.

Net income attributable to controlling shareholders fell from KRW 70.1 billion in 2022 to KRW 573 million in 2023 (down 99.2%) and KRW 279 million in 2024 (down 51.3%) before turning into a net loss of KRW 116.7 billion in 2025. The 2022 peak has been linked to a large rise in equity-method income from affiliates.

The company attributed the 2025 swing to equity-method valuation and impairment on major affiliates. Reports said the Company recognized an impairment of about KRW 133.0 billion on its stake in a KOSDAQ-listed affiliate, after comparing book value with fair value.

Net loss including non-controlling interests was KRW 116.6 billion in 2025.

On a quarterly basis, operating profit of KRW 1.37 billion in Q3 2025 turned into an operating loss of KRW 753 million in Q4 2025, then recovered to KRW 1.77 billion in Q1 2026 and KRW 1.8 billion in Q2 2026, before falling to KRW 932 million in Q3 2026, down 48.2% quarter on quarter.

The Q4 2025 net loss attributable to controlling shareholders of KRW 117.5 billion was the largest quarterly loss in the period. Analysis points to receivables and inventory rising from 15.9% of assets in 2021 to 37.1% in 2025, which increased working-capital pressure.

Operating cash flow was KRW -1.29 billion in 2022 and stayed positive in 2023 (KRW 5.44 billion), 2024 (KRW 2.38 billion) and 2025 (KRW 5.32 billion). The debt ratio at the end of 2025 was 33.6%, down from 53.2% in 2022, and total equity was KRW 146.3 billion.

05

Industry analysis

In Korea's pharmaceutical sector, drug pricing policy is a key driver of profitability. The Company said it is focusing on cost competitiveness ahead of the enforcement of a drug price cut administrative order in 2026. One analysis pointed to higher cost burdens from pricing-policy changes and intensifying competition.

The core generic and prescription drug businesses are directly exposed to price adjustments. The Company said its generics business passed KRW 100 billion in annual sales in 2021. In digestive-system drugs, RD1304 is a candidate that is compared with potassium-competitive acid blockers (P-CABs).

The Company expects higher efficacy and fewer side effects than existing P-CAB treatments, but this is management's expectation before clinical results.

In obesity drugs, the industry view is that Phase 2 costs are large enough that big pharmaceutical companies find it hard to enter, which is one reason the Company is pursuing out-licensing even before Phase 1.

Peers such as Samsung Biologics and Celltrion are built around large-scale manufacturing or biosimilars, whereas PharmGen Science is a mid-sized company focused on domestic prescription drugs, so its competitive arena differs.

The KOSDAQ-listed affiliate has seen earnings slow amid a weaker diagnostics market, which affected the valuation of the stake.

06

Outlook

The Company has set a 2030 revenue target of KRW 283.55 billion, 49.2% above its 2026 target. Its 2027 standalone net income target is KRW 8.28 billion. Analysis suggests that realizing the shareholder-return goal in its corporate value-up plan requires a recovery in net income.

The direction of production capacity has changed. The Company withdrew its plan for a second plant in Osong, a roughly KRW 100 billion project under an investment agreement with Chungcheongbuk-do and Cheongju City signed in November 2022, at a board meeting on 17 November 2026.

It said that the expected profitability of the project had fallen because of changes in the investment environment. Instead, it plans to expand capacity at its Hyangnam plant and broaden its CMO business by introducing dosage forms it did not previously produce.

A company official said the scale of the Hyangnam expansion has not been fixed. The 14,266.6 square metre Osong industrial site will be sold through a public auction process, and the sale price, buyer and timing have not been set.

On R&D, in a May 2026 report the Company said RD1303 and RD1305 would enter the IND approval process within 2026, and that clinical trials for RD2201 were nearing their final stage. It expects results from the affiliates' wellness and aesthetics businesses from 2027. Research headcount expanded from 25 in 2022 to 40 in 2026.

07

Valuation

PER
—
PBR
0.5×
ROE
-72.0%
EPS
-₩7,069
BPS
₩5,674
Dividend per share
₩0

Because net losses attributable to controlling shareholders have continued over the latest four quarters, no earnings-based multiple is currently calculated. Valuation comparison therefore rests mainly on assets.

The price-to-book ratio is below 1x, and the market capitalization sits below total equity of KRW 146.3 billion at the end of 2025. Total equity includes the book value of the affiliate stakes, so after the 2025 impairment, an asset-based reading depends heavily on how those stakes are valued.

Over several years, the Company moved from a profit in 2022 to a loss in 2025, while the debt ratio fell from 53.2% to 33.6% over the same period. The dividend yield is below the sector average. Lower operating profit in Q3 2026 year on year delays the point at which earnings-based multiples can be calculated again.

If earnings recover, the multiple picture will change, so the trend in net income attributable to controlling shareholders in the next annual report is the key checkpoint.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Improving financial capacity

Leverage fell to 33.6% at the end of 2025 from 53.2% in 2022, with total liabilities of KRW 49.1 billion and total equity of KRW 146.3 billion. A press report said net debt moved from KRW 5.88 billion in 2025 to net cash of KRW 12.26 billion in Q1 2026. Operating cash flow stayed positive at KRW 5.32 billion in 2025.

Quarterly operating profit resumed

After an operating loss of KRW 753 million in Q4 2025, operating profit returned to KRW 1.77 billion in Q1 2026. Q2 2026 operating profit was KRW 1.8 billion, up 1.7% quarter on quarter. Q2 2026 revenue was KRW 47.7 billion, which indicates the sales base is holding.

Pipeline milestones in view

The Company plans to enter the IND approval process for RD1303 and RD1305 within 2026, and says RD2201 trials are nearing their final stage. Reports say RD5306 gained potential access to global trials through a technology transfer. Research headcount rose from 25 in 2022 to 40 in 2026.

09

Bear factors

Five consecutive quarterly losses

Net losses attributable to controlling shareholders have run for five consecutive quarters from Q3 2025 to Q3 2026, totaling KRW 134.4 billion over the latest four quarters. The Q4 2025 loss of KRW 117.5 billion was particularly large.

The Q3 2026 loss narrowed to KRW 2.34 billion but remained a loss, and a recovery in earnings power has not yet been shown.

SG&A and R&D burden

Q3 2026 operating profit was KRW 932 million, down 32.2% year on year. Q1 2026 R&D spending more than doubled from the prior-year quarter, and R&D as a share of sales rose from 3.3% to 7.9%. Analysis suggests that higher SG&A absorbs most of the gross profit gains.

Affiliate impairment and working capital

The Company recognized an impairment of about KRW 133.0 billion on its stake in a KOSDAQ-listed affiliate in 2025 after comparing book value with fair value. The share of receivables and inventory rose from 15.9% in 2021 to 37.1% in 2025. Commentary notes that cash collection has slowed relative to sales growth.

10

Risk factors

Drug pricing and policy

The Company is focusing on cost competitiveness ahead of the 2026 drug price cut order. Prescription drugs account for more than 90% of sales, so price adjustments feed directly into revenue and margins. Analysis also points to rising cost burdens from pricing changes and competition.

R&D and clinical entry

Q1 2026 R&D spending more than doubled year on year. If clinical entry is delayed, costs could keep rising without offsetting revenue. Whether RD1303 enters the clinic is widely cited as the key test of the R&D expansion.

Dilution and affiliate volatility

Conversion rights exercised in 2025 raised the total number of issued shares from about 18.2 million to about 21.95 million. Articles of incorporation amendments also set up the basis for issuing redeemable and convertible preferred shares. If affiliate results weaken, equity-method results and impairments could again swing net income.

11

What to watch next

  1. By end-December 2026

    Progress of IND approval for RD1303 and RD1305, which the Company has said would enter the process within 2026. Clinical entry is the milestone that tests whether higher R&D spending is producing results.

  2. Around January–February 2027 (typical timing, date not set)

    Preliminary 2026 annual results. Check whether affiliate valuation effects recur in Q4 and whether the operating margin recovers from 3.5% in 2025.

  3. By 31 March 2027 (statutory filing deadline)

    Filing of the 2026 annual report. This confirms full-year 2026 results, the trend in net income attributable to controlling shareholders and whether the losses persist.

  4. After November 2026, date not set

    Whether the sale price and buyer for the Osong industrial site are confirmed through the public auction. The Company plans to disclose further once the sale is completed.

  5. Fiscal year-end 2027

    Whether the 2027 standalone net income target of KRW 8.28 billion is met, and progress toward the 2030 revenue target of KRW 283.55 billion. This is the benchmark for comparing targets with actual results.

12

Overall view

PharmGen Science's revenue rose for three consecutive years through 2025, but profitability has weakened since 2024. The core driver of the 2025 swing to a loss was an impairment on an affiliate stake. In the core business, higher SG&A and R&D spending is holding down quarterly operating profit in 2026.

The return to operating profit in Q1 2026 and the improvement in net debt are positive for financial capacity.

On the other side, five consecutive quarters of net losses attributable to controlling shareholders, and a combined KRW 134.4 billion loss over the latest four quarters, show that a recovery in earnings power is not yet visible.

The 2030 revenue target and the 2027 standalone net income target are benchmarks for judging execution. The IND approval process for RD1303 and RD1305, the scale of the Hyangnam expansion and the Osong site sale are the next checkpoints.

Because no earnings-based multiple is calculated, valuation rests mainly on asset comparisons, and total equity and the valuation of affiliate stakes are the key variables in reading them.

The trend in operating margin and net income attributable to controlling shareholders in the 2026 annual report is the next scheduled checkpoint.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. bloter.net
  2. m.thebell.co.kr
  3. mt.co.kr
  4. thebionews.net
  5. segyebiz.com
  6. bloter.net
  7. thebionews.net
  8. dealsite.co.kr
  9. m.news.nate.com
  10. pharmnews.com
  11. vegannews.co.kr
  12. wcomp.fnguide.com
  13. v.daum.net
  14. comp.fnguide.com
  15. judal.co.kr
  16. news.nate.com
  17. pflow.keywordegg.com
  18. accidentalorder.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis